Neodolpasse (Diclofenac Sodium, Orphenadrine Citrate)

Diclofenac Sodium and Orphenadrine Citrate, the active ingredients in Neodolpasse, are a non‑steroidal anti‑inflammatory drug and a centrally acting muscle relaxant presented as an injectable solution for intravenous use. They are indicated for the management of acute pain, inflammation and muscle spasm in adult patients.

GNH USA supplies Neodolpasse as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neodolpasse combines an NSAID and a muscle relaxant to address conditions involving pain, inflammation and spasm.

Acute pain: provides rapid analgesia and reduces inflammatory mediators. Inflammation: diminishes prostaglandin synthesis to limit swelling. Muscle spasm: relaxes skeletal muscle tone through central anticholinergic action.

Neodolpasse may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Gastrointestinal discomfort or dyspepsia. - Headache or dizziness. - Injection site pain or erythema. - Transient elevation of liver enzymes. - Mild hypotension. - Nausea or vomiting.

Serious or Rare Side Effects: - Severe allergic reactions such as anaphylaxis. - Hepatotoxicity with marked liver enzyme rise. - Renal impairment or acute kidney injury. - Gastrointestinal ulceration or bleeding. - Cardiac events including myocardial infarction. - Severe skin reactions like Stevens‑Johnson syndrome.

Before using Neodolpasse, consider the following safety measures.

Renal function: assess baseline kidney status, especially in patients with chronic disease. Hepatic health: monitor liver enzymes in patients with existing liver conditions. Cardiovascular risk: use cautiously in individuals with known heart disease or hypertension. Bleeding tendency: avoid in patients with active ulcers or coagulopathy. Pregnancy and lactation: safety not established; weigh benefits against potential risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Neodolpasse can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other NSAIDs or COX‑2 inhibitors: heightened gastrointestinal toxicity. - Lithium: diclofenac may raise lithium serum levels. - MAO inhibitors: potential for hypertensive crisis with orphenadrine. - Cytochrome P450 inhibitors: may elevate diclofenac concentrations.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: possible reduction in renal function. - Diuretics: may enhance nephrotoxic potential. - Corticosteroids: additive risk of GI ulceration. - SSRIs or SNRIs: increased bleeding tendency. - Antihypertensives: orphenadrine may counteract blood pressure control.